Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic.
| Title: | Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic. |
|---|---|
| Authors: | Haider B; Alkermes, Inc, Waltham, MA, USA.; O'Sullivan AK; Alkermes, Inc, Waltham, MA, USA.; Bessonova L; Alkermes, Inc, Waltham, MA, USA.; Keane E; Alkermes, Inc, Waltham, MA, USA.; Achtyes E; Cherry Health and the Michigan State University College of Human Medicine, Grand Rapids, MI, USA.; Harvey PD; University of Miami Miller School of Medicine, Miami, FL, USA.; Kane JM; The Zucker Hillside Hospital, Glen Oaks, NY, USA.; Saklad SR; College of Pharmacy, University of Texas at Austin, Pharmacotherapy Division, San Antonio, TX, USA.; Trotter JP; Worldwide Clinical Trials, Research Triangle, NC, USA.; Claxton A; Alkermes, Inc, Waltham, MA, USA.; Polak T; Alkermes, Inc, Waltham, MA, USA.; McGrory J; Alkermes, Inc, Waltham, MA, USA.; Noori W; Alkermes, Inc, Waltham, MA, USA.; Sikora Kessler A; QualityMetric Incorporated, LLC, Johnston, RI, USA.; Yarlas A; QualityMetric Incorporated, LLC, Johnston, RI, USA.; Velligan D; University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. |
| Source: | Neuropsychiatric disease and treatment [Neuropsychiatr Dis Treat] 2023 Mar 17; Vol. 19, pp. 623-634. Date of Electronic Publication: 2023 Mar 17 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101240304 Publication Model: eCollection Cited Medium: Print ISSN: 1176-6328 (Print) Linking ISSN: 11766328 NLM ISO Abbreviation: Neuropsychiatr Dis Treat Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Albany, Auckland, N.Z. : Dove Medical Press, c2005- |
| Abstract: | Purpose: The COVID-19 pandemic substantially impacted care of patients with schizophrenia treated with long-acting injectable antipsychotics (LAIs). This study (OASIS-MAPS) examined how clinical sites adapted operations and used telepsychiatry to maintain standard of care for these patients during the pandemic.; Methods: Two online surveys (initial: October-November 2020, N = 35; follow-up: July-September 2021, N = 21) were completed by a principal investigator (PI) or PI-appointed designee at sites participating in the OASIS study (NCT03919994). Survey responses were analyzed descriptively.; Results: At the time of the initial survey, all 35 participating sites were using variants of telepsychiatry, with 20 sites adopting it after the pandemic started. Most sites reported no negative impacts of the pandemic on medication adherence, although approximately 20% of sites reported decreased adherence for LAIs. Twelve sites (34%) reported switching patients with schizophrenia from LAIs to oral antipsychotic medications, while 11 sites (31%) reported switching patients from shorter to longer injection interval LAIs during the pandemic. Most sites did not experience difficulties in implementing or expanding telepsychiatry services, although lower reimbursement rate for telepsychiatry and patients' lack of access to and training on relevant technologies were the most frequently reported barriers.; Conclusion: Changes made by sites after the pandemic onset were viewed by almost all participants as satisfactory for maintaining standard of care. Almost all participants thought that the use of telepsychiatry services would continue after the pandemic in a hybrid manner combining telepsychiatry and office visits. Ensuring that patients have equitable access to telepsychiatry will be important in the post-pandemic future.; (© 2023 Haider et al.) |
| Competing Interests: | Batool Haider, James McGrory, and Elizabeth Keane are employees of Alkermes, Inc., a pharmaceutical company which manufactures products including antipsychotic medications for people with schizophrenia and bipolar I disorder. These authors may be shareholders. Amy K. O’Sullivan, Leona Bessonova, Amy Claxton, Tiffany Polak, and Wahidullah Noori were employees of Alkermes, Inc. at the time this study was conducted. Asia Sikora Kessler and Aaron Yarlas were employees of QualityMetric Incorporated, LLC, a consulting company specializing in health measurement solutions, which was paid by Alkermes, Inc. for assistance in study design, analyses, and manuscript development, at the time this study was conducted. Eric Achtyes has consulted or served on advisory boards for Alkermes Inc., and has received research grants and/personal fees from Alkermes, Inc, Biogen, Boehringer Ingelheim, Janssen, Neurocrine Biosciences, Takeda, Atheneum, Karuna, Lundbeck, Otsuka, Sunovion, Teva; briefly owned stock from AstraZeneca, Johnson and Johnson, Moderna, and Pfizer, outside the submitted work. Philip D. Harvey, John M. Kane, Stephen R. Saklad, and Dawn Velligan have served as paid consultants for Alkermes, Inc. Philip D. Harvey reports personal fees from Bioexcel, Boehringer Ingelheim, Karuna Pharma, Merck Pharma, Minerva Pharma, Roche Pharma, Sunovion Pharma, principal investigator for iFunction, royalties from WCG Verasci, payment for grant reviews from Alkermes, outside the submitted work. John M. Kane reports personal fees from Alkermes, Allergan, Boehringer Ingelheim, Indivior, Intracellular Therapies, Johnson & Johnson, Merck, Minerva, Neurocrine, HLS, HealthRhythms; personal fees from and shareholder of LB Pharmaceuticals, Vanguard Research Group, North Shore Therapeutics; grants and personal fees from Janssen Pharmaceutical, Sunovion; personal fees from and advisory board of Newron, Novartis, Otsuka, Teva, Click Therapeutics, Cerevel, Dainippon Sumitomo, H. Lundbeck; royalties from UpToDate, outside the submitted work. Dawn Velligan reports grants and/or personal fees from Alkermes, Indivior, Otsuka, Karuna, and Janssen, during the conduct of the study. Jeffrey Trotter is an employee of Worldwide Clinical Trials, a clinical research vendor paid by Alkermes, Inc. The authors report no other conflicts of interest in this work. |
| References: | Can J Psychiatry. 2021 Sep;66(9):815-826. (PMID: 33464115); BMC Psychiatry. 2018 May 18;18(1):135. (PMID: 29776393); Curr Opin Psychiatry. 2021 May 1;34(3):203-210. (PMID: 33587494); Lancet Psychiatry. 2021 Sep;8(9):797-812. (PMID: 34274033); Prim Care Companion CNS Disord. 2020 Oct 1;22(5):. (PMID: 33002350); Clin Schizophr Relat Psychoses. 2014 Apr;8(1):21-27A. (PMID: 23428781); J Clin Psychiatry. 2021 Jan 12;82(1):. (PMID: 33434959); Schizophr Res. 2020 Sep;223:192-198. (PMID: 32771308); Eur J Psychiatry. 2021 Jul-Sep;35(3):204-205. (PMID: 34121789); Schizophr Res. 2020 Aug;222:532-533. (PMID: 32389613); J Med Econ. 2018 Feb;21(2):127-134. (PMID: 28895758); Psychiatr Serv. 2004 Aug;55(8):886-91. (PMID: 15292538); J Affect Disord. 2021 Jul 1;290:279-283. (PMID: 34015622); J Telemed Telecare. 2020 Jan-Feb;26(1-2):14-20. (PMID: 30134781); Clin Drug Investig. 2017 Oct;37(10):947-956. (PMID: 28726075); J Korean Med Sci. 2020 Jun 29;35(25):e237. (PMID: 32597048); Psychol Serv. 2012 May;9(2):111-131. (PMID: 22662727); Schizophr Res. 2020 Jun;220:265-266. (PMID: 32349886); Cureus. 2021 Aug 7;13(8):e16974. (PMID: 34540384); JAMA Psychiatry. 2020 Sep 1;77(9):891-892. (PMID: 32242888); Perspect Psychiatr Care. 2021 Oct;57(4):1991-1998. (PMID: 33938567); J Med Internet Res. 2021 Mar 15;23(3):e23984. (PMID: 33720028); Schizophr Bull. 2016 Mar;42(2):448-55. (PMID: 26400871); J Affect Disord. 2021 Feb 15;281:13-23. (PMID: 33279864); J Telemed Telecare. 2022 Jun;28(5):311-330. (PMID: 32746762); Psychiatry Res. 2010 Apr 30;176(2-3):109-13. (PMID: 20185182); JAMA Psychiatry. 2021 Apr 1;78(4):380-386. (PMID: 33502436); Psychiatr Serv. 2019 Mar 1;70(3):225-228. (PMID: 30651059); Gen Hosp Psychiatry. 2020 Jan - Feb;62:28-36. (PMID: 31775066); BMC Psychiatry. 2013 Feb 08;13:50. (PMID: 23394123); J Manag Care Spec Pharm. 2021 Oct;27(10-a Suppl):S2-S13. (PMID: 34652218); Curr Psychiatry Rep. 2021 Jul 23;23(9):61. (PMID: 34297202); Psychiatriki. 2021 Sep 20;32(3):219-223. (PMID: 34390554); World Psychiatry. 2013 Oct;12(3):216-26. (PMID: 24096780) |
| Contributed Indexing: | Keywords: care management; coronavirus; medication adherence; telehealth |
| Molecular Sequence: | ClinicalTrials.gov NCT03919994 |
| Entry Date(s): | Date Created: 20230324 Latest Revision: 20230325 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10029934 |
| DOI: | 10.2147/NDT.S394220 |
| PMID: | 36959874 |
| Database: | MEDLINE |
Journal Article